Issue 4, 2024

A new era in cancer treatment: harnessing ZIF-8 nanoparticles for PD-1 inhibitor delivery

Abstract

This review delves into the potential of zeolitic imidazolate framework-8 (ZIF-8) nanoparticles in augmenting the efficacy of cancer immunotherapy, with a special focus on the delivery of programmed cell death receptor 1 (PD-1) inhibitors. The multifunctional nature of ZIF-8 nanoparticles as drug carriers is emphasized, with their ability to encapsulate a range of therapeutic agents, including PD-1 inhibitors, and facilitate their targeted delivery to tumor locations. By manipulating the pore size and surface characteristics of ZIF-8 nanoparticles, controlled drug release can be realized. The strategic use of ZIF-8 nanoparticles to deliver PD-1 inhibitors presents a precise and targeted modality for cancer treatment, reducing off-target impacts and enhancing therapeutic effectiveness. This combined strategy addresses the existing challenges and constraints of current immunotherapy techniques, with the ultimate goal of enhancing patient outcomes in cancer therapy.

Graphical abstract: A new era in cancer treatment: harnessing ZIF-8 nanoparticles for PD-1 inhibitor delivery

Article information

Article type
Review Article
Submitted
19 Okt. 2023
Accepted
11 Dec. 2023
First published
11 Dec. 2023

J. Mater. Chem. B, 2024,12, 872-894

A new era in cancer treatment: harnessing ZIF-8 nanoparticles for PD-1 inhibitor delivery

F. Rastin, M. A. Oryani, S. Iranpour, H. Javid, A. Hashemzadeh and M. Karimi-Shahri, J. Mater. Chem. B, 2024, 12, 872 DOI: 10.1039/D3TB02471G

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements